Print this page
immunotherapy
-
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Liver -
Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations.
Protocol: 072107Principal Investigator:
- Henry Richard Alexander
Applicable Disease Sites: Pancreas -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
A Phase 3, Multicenter, Randomized, Open-Label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer.
Protocol: 072509Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Other Digestive Organ -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
A Phase 3, Multicenter, Randomized, Open-Label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer.
Protocol: 072509Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Other Digestive Organ -
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer.
Protocol: 072511Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Colon -
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Protocol: 082105Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Protocol: 082105Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Single-Arm, Open-Label, Multicenter, Phase II Clinical Study to Evaluate the Tolerability, Safety, and Preliminary Efficacy of Intravesical Administration of Herpes Virus T3011 Injection in Participants with BCG-unresponsive High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
Protocol: 082504Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
A Single-Arm, Open-Label, Multicenter, Phase II Clinical Study to Evaluate the Tolerability, Safety, and Preliminary Efficacy of Intravesical Administration of Herpes Virus T3011 Injection in Participants with BCG-unresponsive High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).
Protocol: 082504Principal Investigator:
- Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer.
Protocol: 082603Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Urinary Bladder -
Phase III Double-Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma.
Protocol: 082608Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer.
Protocol: 082603Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Urinary Bladder -
Phase III Double-Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma.
Protocol: 082608Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney